Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895631 · ClinicalTrials.gov registry record · Phase 3
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
A Phase 3 study of Hyperparathyroidism, Primary, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT04895631 is a Phase 3 study of Hyperparathyroidism, Primary that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 140 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04895631, a Phase 3 study of Hyperparathyroidism, Primary, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
Conditions Studied
Interventions
- DRUG 18F-Fluorocholine
- PROCEDURE Positron emission tomography (PET)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04895631
The ClinicalTrials.gov registry entry for NCT04895631 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperparathyroidism, Primary appearing as the primary indexed condition, and to 2 interventions - of which 18F-Fluorocholine is the first listed.
NCT04895631 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04895631 about?
NCT04895631 is a clinical study titled "18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas". This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
What is the current status of trial NCT04895631?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2021-06-30. Estimated completion is 2027-06-30.
What conditions does trial NCT04895631 study?
This clinical trial studies the following conditions: Hyperparathyroidism, Primary.
What interventions are being tested in trial NCT04895631?
The interventions under investigation include: 18F-Fluorocholine (DRUG), Positron emission tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT04895631?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895631 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperparathyroidism, Primary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.